Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance

Overview

Journal Science

Specialty Science

Date 2010 Jun 5

PMID 20522774

Citations 379

Authors

Jesse D Bloom

Lizhi Ian Gong

David Baltimore

Affiliations

Soon will be listed here.

Abstract

The His274-->Tyr274 (H274Y) mutation confers oseltamivir resistance on N1 influenza neuraminidase but had long been thought to compromise viral fitness. However, beginning in 2007-2008, viruses containing H274Y rapidly became predominant among human seasonal H1N1 isolates. We show that H274Y decreases the amount of neuraminidase that reaches the cell surface and that this defect can be counteracted by secondary mutations that also restore viral fitness. Two such mutations occurred in seasonal H1N1 shortly before the widespread appearance of H274Y. The evolution of oseltamivir resistance was therefore enabled by "permissive" mutations that allowed the virus to tolerate subsequent occurrences of H274Y. An understanding of this process may provide a basis for predicting the evolution of oseltamivir resistance in other influenza strains.

Citing Articles

Integrated virtual screening and compound generation targeting H275Y mutation in the neuraminidase gene of oseltamivir-resistant influenza strains.

Khan W, Khan N, Tembhre M, Malik Z, Ansari M, Mishra A Mol Divers. 2025; .

PMID: 40085404 DOI: 10.1007/s11030-025-11163-0.

Immune history shapes human antibody responses to H5N1 influenza viruses.

Garretson T, Liu J, Li S, Scher G, Santos J, Hogan G Nat Med. 2025; .

PMID: 40082696 DOI: 10.1038/s41591-025-03599-6.

Discovering Influenza Virus Neuraminidase Inhibitors via Computational and Experimental Studies.

Nguyen T, Anh Pham N, Thai Q, Vu V, Ngo S, Horng J ACS Omega. 2024; 9(49):48505-48511.

PMID: 39676983 PMC: 11635487. DOI: 10.1021/acsomega.4c07194.

Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.

Mercuri F, White S, McQuilten H, Lemech C, Mynhardt S, Hari R ERJ Open Res. 2024; 10(6).

PMID: 39655168 PMC: 11626610. DOI: 10.1183/23120541.00199-2024.

Optimized production of a truncated form of the recombinant neuraminidase of influenza virus in Escherichia coli as host with suitable functional activity.

Shariati F, Fotouhi F, Farahmand B, Barghi Z, Azadmanesh K Microb Cell Fact. 2024; 23(1):318.

PMID: 39582000 PMC: 11587648. DOI: 10.1186/s12934-024-02587-8.

References

Li Wan Po A, Farndon P, Palmer N . Maximizing the value of drug stockpiles for pandemic influenza. Emerg Infect Dis. 2009; 15(10):1686-7. PMC: 2866417. DOI: 10.3201/eid1510.090844. View

Liu C, Eichelberger M, Compans R, Air G . Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol. 1995; 69(2):1099-106. PMC: 188682. DOI: 10.1128/JVI.69.2.1099-1106.1995. View

Nelson M, Edelman L, Spiro D, Boyne A, Bera J, Halpin R . Molecular epidemiology of A/H3N2 and A/H1N1 influenza virus during a single epidemic season in the United States. PLoS Pathog. 2008; 4(8):e1000133. PMC: 2495036. DOI: 10.1371/journal.ppat.1000133. View

Moscona A . Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353(13):1363-73. DOI: 10.1056/NEJMra050740. View

Rambaut A, Pybus O, Nelson M, Viboud C, Taubenberger J, Holmes E . The genomic and epidemiological dynamics of human influenza A virus. Nature. 2008; 453(7195):615-9. PMC: 2441973. DOI: 10.1038/nature06945. View

Abed Y, Goyette N, Boivin G . A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther. 2004; 9(4):577-81. View

Nayak D, Balogun R, Yamada H, Zhou Z, Barman S . Influenza virus morphogenesis and budding. Virus Res. 2009; 143(2):147-61. PMC: 2730999. DOI: 10.1016/j.virusres.2009.05.010. View

Ortlund E, Bridgham J, Redinbo M, Thornton J . Crystal structure of an ancient protein: evolution by conformational epistasis. Science. 2007; 317(5844):1544-8. PMC: 2519897. DOI: 10.1126/science.1142819. View

Wagner R, Matrosovich M, Klenk H . Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol. 2002; 12(3):159-66. DOI: 10.1002/rmv.352. View

10.

Mitraki A, Fane B, Sturtevant J, King J . Global suppression of protein folding defects and inclusion body formation. Science. 1991; 253(5015):54-8. DOI: 10.1126/science.1648264. View

11.

Liang Y, Hong Y, Parslow T . cis-Acting packaging signals in the influenza virus PB1, PB2, and PA genomic RNA segments. J Virol. 2005; 79(16):10348-55. PMC: 1182667. DOI: 10.1128/JVI.79.16.10348-10355.2005. View

12.

Schrag S, Perrot V, Levin B . Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc Biol Sci. 1997; 264(1386):1287-91. PMC: 1688596. DOI: 10.1098/rspb.1997.0178. View

13.

Russell R, Haire L, Stevens D, Collins P, Lin Y, Blackburn G . The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006; 443(7107):45-9. DOI: 10.1038/nature05114. View

14.

Simonsen L, Viboud C, Grenfell B, Dushoff J, Jennings L, Smit M . The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol. 2007; 24(8):1811-20. DOI: 10.1093/molbev/msm103. View

15.

Ives J, Carr J, Mendel D, Tai C, Lambkin R, Kelly L . The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002; 55(2):307-17. DOI: 10.1016/s0166-3542(02)00053-0. View

16.

Wang X, Minasov G, Shoichet B . Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol. 2002; 320(1):85-95. DOI: 10.1016/S0022-2836(02)00400-X. View

17.

Poteete A, Rennell D, Bouvier S, Hardy L . Alteration of T4 lysozyme structure by second-site reversion of deleterious mutations. Protein Sci. 1998; 6(11):2418-25. PMC: 2143591. DOI: 10.1002/pro.5560061115. View

18.

Suzuki T, Takahashi T, Guo C, Hidari K, Miyamoto D, Goto H . Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. J Virol. 2005; 79(18):11705-15. PMC: 1212606. DOI: 10.1128/JVI.79.18.11705-11715.2005. View

19.

Bloom J, Labthavikul S, Otey C, Arnold F . Protein stability promotes evolvability. Proc Natl Acad Sci U S A. 2006; 103(15):5869-74. PMC: 1458665. DOI: 10.1073/pnas.0510098103. View

20.

Bloom J, Glassman M . Inferring stabilizing mutations from protein phylogenies: application to influenza hemagglutinin. PLoS Comput Biol. 2009; 5(4):e1000349. PMC: 2664478. DOI: 10.1371/journal.pcbi.1000349. View